Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors

Learn more about:
Related Clinical Trial
The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor International Pediatric Adrenocortical Tumor Registry Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Structured Evaluation of adRENal Tumors Discovered Incidentally – Prospectively Investigating the Testing Yield Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Possible New Therapy for Advanced Cancer IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Studying Genes in Samples From Younger Patients With Adrenocortical Tumor Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Evaluation of Side Effects of Mitotane Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Sunitinib in Refractory Adrenocortical Carcinoma Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma Cabozantinib in Advanced Adrenocortical Carcinoma Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma German Adrenocortical Carcinoma Registry Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Brief Title

Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors

Official Title

A Phase I Trial of Suramin With Sequential Doxorubicin in Patients With Advanced Solid Tumors

Brief Summary

      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy with suramin
      plus doxorubicin in treating patients with advanced solid tumors.

Detailed Description

      OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of suramin followed by doxorubicin
      in patients with advanced solid tumors. II. Describe the toxic effects of suramin with
      sequential doses of doxorubicin in these patients. III. Assess the development of peripheral
      neuropathy in patients with this treatment. IV. Assess the preliminary evidence of the
      antitumor effect of this regimen in these patients. VI. Explore the relationships between the
      pharmacokinetic parameters and potential neurotoxicity of suramin in these patients.

      OUTLINE: This is a dose-escalation study of doxorubicin. Patients receive suramin IV daily
      over 1-2 hours on days 1-4 followed by doxorubicin IV over 10-15 minutes on day 5. Treatment
      repeats every 4 weeks for up to 3 courses in the absence of unacceptable toxicity, disease
      progression, or clinical deterioration. Starting from course 4, patients receive alternating
      courses of doxorubicin IV on day 1 every 4 weeks (courses 4, 6, 8, etc.) and suramin with
      doxorubicin (courses 5, 7, 9 etc.) as described above. Cohorts of 3-6 patients receive
      escalating doses of doxorubicin until the maximum tolerated dose (MTD) is determined. The MTD
      is defined as the dose preceding that at which 2 or more of 6 patients experience
      dose-limiting toxicity. Stable patients who achieve disease response and are able to receive
      a target cumulative dose of doxorubicin may discontinue doxorubicin and receive suramin alone
      every 8 weeks. Patients are followed at 3 months.

      PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study within 1 year.

Study Phase

Phase 1

Study Type



Adrenocortical Carcinoma


doxorubicin hydrochloride


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Start Date

October 1997

Completion Date

January 2003

Primary Completion Date

January 2003

Eligibility Criteria

        DISEASE CHARACTERISTICS: Histologic or cytologic confirmation of malignant solid tumor
        including, but not limited to: Breast cancer Prostate cancer Colon cancer Adrenocortical
        tumors No CNS metastases No conventional therapy for cure or palliation available

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count
        at least 100,000/mm3 Hepatic: aPTT and PT no greater than upper limit of normal (ULN)
        Bilirubin no greater than 1.5 times ULN AST no greater than 2 times ULN Albumin at least
        3.0 g/dL Renal: Creatinine clearance at least 50 mL/min Sodium and potassium normal
        Cardiovascular: Ejection fraction normal if prior doxorubicin therapy No New York Heart
        Association class III or IV heart disease No history of significant cardiac arrhythmia No
        history of congestive heart failure Neurologic: No seizure disorder No grade 2 or greater
        peripheral neuropathy Other: Not pregnant or nursing Negative pregnancy test Fertile
        patients must use effective contraception No insulin-dependent diabetes mellitus No
        uncontrolled infection No chronic debilitating disease

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy
        or immunotherapy No concurrent immunotherapy No concurrent filgrastim (G-CSF) or
        sargramostim (GM-CSF) Chemotherapy: More than 4 weeks since prior chemotherapy (6 weeks for
        mitomycin or nitrosoureas) and recovered Prior doxorubicin allowed if total dose less than
        300 mg/m2 No other concurrent chemotherapy No more than 2 prior chemotherapy regimens for
        metastatic disease Endocrine therapy: No current steroid use of greater than 1.5 mg
        dexamethasone (or equivalent) per day Radiotherapy: At least 4 weeks since prior radiation
        therapy No radiation therapy to greater than 25% of bone marrow No concurrent radiotherapy
        Surgery: At least 4 weeks since prior major surgery




18 Years - N/A

Accepts Healthy Volunteers



Alex A. Adjei, MD, PhD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Study Sponsor

Mayo Clinic


 National Cancer Institute (NCI)

Study Sponsor

Alex A. Adjei, MD, PhD, Study Chair, Mayo Clinic

Verification Date

August 2011